

Supplementary Online Content

Fujimoto D, Morimoto T, Tamiya M, et al. Outcomes of chemoimmunotherapy among patients with extensive-stage small cell lung cancer according to potential clinical trial eligibility. *JAMA Netw Open*. 2023;6(2):e230698.
doi:10.1001/jamanetworkopen.2023.0698

eTable 1. Key Eligibility Criteria of Previous Pivotal Trials

eTable 2. Treatment-Related Adverse Events (AEs)

eFigure 1. Study Profile

eFigure 2. Kaplan-Meier Survival Curves: Progression-Free Survival and Overall Survival Stratified by Eligibility Criteria 2

eFigure 3. Kaplan-Meier Survival Curves: Progression-Free Survival and Overall Survival Stratified by Performance Status

eFigure 4. Kaplan-Meier Survival Curves: Progression-Free Survival and Overall Survival Stratified by Age

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Key eligibility criteria of previous pivotal trials

ECOG performance status of 0 or 1
Patients without symptomatic central nervous system metastases^a
Adequate hematologic and end organ function defined by the following laboratory test findings Absolute neutrophil count \geq 1500 cells/ μ L Lymphocyte count \geq 500/ μ L Platelet count \geq 100,000/ μ L Hemoglobin \geq 9.0 g/dL Aspartate aminotransferase and alanine aminotransferase $<$ 100 U/L Serum bilirubin $<$ 1.25 \times ULN Serum creatinine $<$ 1.5 \times ULN
Patients without malignancies other than SCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcomes
Patients without a history of autoimmune diseases Patients with a history of autoimmune-related hypothyroidism on thyroid replacement hormone therapy are eligible. Patients with controlled type I diabetes mellitus on an insulin regimen are eligible.
Patients without a history of interstitial lung diseases other than radiation pneumonitis
Patients who did not receive treatment with systemic immunosuppressive medications
Patients without uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures


^a Patients with untreated asymptomatic brain metastases are eligible in criteria 1 but ineligible in criteria 2

Abbreviations: ECOG, Eastern Cooperative Oncology Group; SCLC, small-cell lung cancer


eTable 2. Treatment-related adverse events (AEs)

Non-hematologic AEs, no. (%)	Grades 3–5	Grade 5
Any	64 (31)	4 ^a (2)
Event occurring in ≥3 patients, no.		
Febrile neutropenia	27 (13)	
Pneumonitis	7 (3)	2
Lung infection	6 (3)	1
Skin disorders	3 (1)	
Nausea	4 (2)	
Alkaline phosphatase increased	3 (1)	
Hyperglycemia	3 (1)	
Hyponatremia	3 (1)	
Hematologic AEs, no. (%)	Grades 4	
Any	73 (35)	
Neutropenia	70 (34)	
Anemia	0 (0)	
Thrombocytopenia	9 (4)	

^a Including one hepatic failure.




eFigure1. Study profile.



Number at risk



Eligible	116	110	82	46	27	20	14	9	6	3
Ineligible	91	80	62	32	14	11	10	3	1	1




Number at risk

Eligible	116	113	107	92	85	75	68	54	39	25
Ineligible	91	85	79	70	62	53	50	30	19	14

eFigure 2. Kaplan–Meier survival curves. (A) Progression-free survival and (B) overall survival stratified by eligibility criteria 2.




eFigure 3. Kaplan–Meier survival curves. (A) Progression-free survival and (B) overall survival stratified by performance status (PS).



Number at risk

	0	2	4	6	8	10	12	14	16	18
≥ 75 years	64	57	40	20	11	6	4	1	1	1
< 75 years	143	133	104	58	30	25	20	11	6	3



Number at risk

	0	2	4	6	8	10	12	14	16	18
≥ 75 years	64	59	56	44	34	31	29	19	14	9
< 75 years	143	139	130	118	113	97	89	65	44	30

eFigure 4. Kaplan–Meier survival curves. (A) Progression-free survival and (B) overall survival stratified by age.